Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Informatics

Roche signs drug discovery pact with machine-learning firm Recursion

by Ryan Cross
December 17, 2021 | A version of this story appeared in Volume 99, Issue 45

 

Recursion, a company that uses machine learning for drug discovery, is partnering with Roche and its subsidiary Genentech to identify novel drug targets and develop drugs against them. The firms will rely heavily on single-cell data for neuroscience and cancer indications. The partnership could include up to 40 drug programs. Roche will pay Recursion $150 million up front and potentially more than $300 million in milestone payments for each program.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.